Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer

HER2-positive Breast Cancer Clinical Trial

— SHERO  

Official title:

Adjuvant Dual Anti-HER2 Therapy in Patients With Tumors < 8mm, Node-negative, HER2-positive Breast Cancer :a Single-group Arm, Open-label, Prospective, Phase 2 Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04158856
• Other study ID #: SHERO
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: June 1, 2020
• Est. completion date: May 31, 2030

Study information

• Verified date: November 2019
• Source: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Contact: Xuexin He, MD
• Phone: +86-18329139569
• Email: xuexinhe[@]zju.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial aims to study the efficacy and safety of adjuvant Pyrotinib plus trastuzumab in patients with tumors <8mm, node-negative, HER2-positive breast cancer.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: May 31, 2030
• Est. primary completion date: May 31, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Women aged 18-70 years old

2. Have finished radical operation

3. Histologically confirmed invasive ductal carcinoma (IDCA)

4. According to AJCC ,pT<8mm, pN0, no evidence for metastasis

5. Operation specimens are available for ER, progesterone receptor (PR) and HER2 detection, patients should be HER2 positive tumor (IHC staining of 3+ [uniform, intense membrane staining of >30% of invasive tumor cells], or a FISH result of .6 HER2 gene copies per nucleus or a FISH ratio [HER2 gene signals to chromosome 17 signals] of >2.2), nuclear grade 3.

6. Should have tumor tissue available and sufficient for multi-spots sampling.

7. It has been <84 days since the date of definitive surgery, and there is adequate wound healing as determined by the Treating Physician.

8. Has Eastern Cooperative Oncology Group (ECOG) Performance Score 0-1, expected survival time > 12 months

9. Cardiac function had to be within normal limits (left ventricular ejection fraction [LVEF] =50%), as established by multiple gated acquisition scan or echocardiography.

10. Adequate bone marrow function, adequate liver and renal function, and adequate coagulation function.

11. Women with potential child-bearing must have a negative pregnancy test (urine or serum) within 7 days of drug administration and agree to use an acceptable and effective method of contraception to avoid pregnancy during the study.

12. Written informed consent according to the local ethics committee requirements.

Exclusion Criteria:

1. pT=8mm or node positive

2. Metastatic breast cancer

3. Any prior systemic or loco-regional treatment of breast cancer, including chemotherapy in 28 days

4. With a history of malignant tumor except uterine cervix cancer in situ or skin basal cell carcinoma

5. Patients with medical conditions that indicate intolerant to adjuvant target therapy and related treatment, including severe infection, coagulation disorder, active peptic ulcer, coagulation disorder, connective tissue disease or myelo-suppressive disease

6. Has symptomatic peripheral neuropathy > grade 2 according to NCI

7. Known severe allergy to any drugs in this study

8. Has cardiac dysfunction or lung dysfunction defined as follows:

• grade =3 CHF according to NCI CTCAE v 5.0 or NYHA=II

• angina which requires drug control, cardiac infraction, and any other vascular disease with apparent clinical symptoms

• uncontrolled high-risk arrhythmia

• uncontrolled hypertension

9. Has active hepatitis B or hepatitis C with abnormal liver function tests (LFTs) or is known to be HIV positive

10. Patient is pregnant or breast feeding

Related Conditions & MeSH terms

• Breast Neoplasms
• HER2-positive Breast Cancer

Intervention

Drug:
• Pyrotinib
400mg po every day
• Trastuzumab
Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg every 21 days

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
xuexin he

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease-free Survival	stimated percentage of patients alive and disease-free at 5 years from randomization or censored at date of last follow-up.	5 years
Secondary	Breast Cancer Specific Survival	Estimated percentage of patients alive and disease-free at 5 years from randomization, where breast cancer specific survival is defined as the time from randomization to death from breast cancer relapse; or censored at date last known alive.	5 years
Secondary	Overall Survival	Estimated percentage of patients alive and disease-free at 5 years from randomization, where overall survival is defined as the time from randomization to death from any cause; or censored at date last known alive.	5 years
Secondary	Treatment-related adverse events	Incidence and severity of adverse events as assessed by NCI CTCAE V5.0	up to 3 months
Secondary	Change of LVEF after treatment	The change of LVEF after 3 months treatment compared to the baseline LVEF	up to 3 months